Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30275314 | 0.83 | EGFR (0.54) | EGFRPDGFRBMAPTALDH1A1CYP3A4 | |
| SCHEMBL1469486 | 0.83 | EGFR (0.54) | EGFRPDGFRBMAPTALDH1A1CYP3A4 | |
| SCHEMBL2997470 | 0.82 | EGFR (0.50) | EGFRPDGFRBMAPTALDH1A1CYP3A4 | |
| SCHEMBL29719028 | 0.81 | EGFR (0.41) | EGFRMAPTALDH1A1TDP1MEN1 | |
| SCHEMBL29719180 | 0.81 | EGFR (0.41) | EGFR | |
| SCHEMBL22983685 | 0.81 | EGFR (0.41) | EGFR | |
| SCHEMBL14579636 | 0.81 | GAA (0.43) | EGFRMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL25409 | 0.81 | EGFR (0.41) | EGFRMAPTALDH1A1TDP1MEN1 | |
| SCHEMBL12488021 | 0.81 | EGFR (0.46) | EGFRMAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL4781507 | 0.79 | EGFR (0.40) | EGFRMAPTALDH1A1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127383-A1 | NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT | RENOTARGET THERAPEUTICS INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127383-A1 | NOVEL CLASS OF QUINOLONE HETEROCYCLIC AROMATIC MOLECULES FOR CANCER TREATMENT | EGFR, NRAS, ABL1 | EGFR 1/4885PDGFRB 99/4885MAPT 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.